Cargando…
Anti-tumour activity of bisphosphonates in preclinical models of breast cancer
There is increasing evidence of anti-tumour effects of bisphosphonates from pre-clinical studies, supporting a role for these drugs beyond their traditional use in treatment of cancer-induced bone disease. A range of model systems have been used to investigate the effects of different bisphosphonate...
Autores principales: | Holen, Ingunn, Coleman, Robert E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046431/ https://www.ncbi.nlm.nih.gov/pubmed/21176176 http://dx.doi.org/10.1186/bcr2769 |
Ejemplares similares
-
Tumour macrophages as potential targets of bisphosphonates
por: Rogers, Thea L, et al.
Publicado: (2011) -
The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway
por: Wilson, Caroline, et al.
Publicado: (2015) -
The role of bisphosphonates in breast cancer: The present and future role of bisphosphonates in the management of patients with breast cancer
por: Brown, Janet E, et al.
Publicado: (2002) -
Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence
por: Santini, Daniele, et al.
Publicado: (2015) -
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)